Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants.
Mäkelä AR, Uğurlu H, Hannula L, Kant R, Salminen P, Fagerlund R, Mäki S, Haveri A, Strandin T, Kareinen L, Hepojoki J, Kuivanen S, Levanov L, Pasternack A, Naves RA, Ritvos O, Österlund P, Sironen T, Vapalahti O, Kipar A, Huiskonen JT, Rissanen I, Saksela K.
Mäkelä AR, et al.
Nat Commun. 2023 Mar 24;14(1):1637. doi: 10.1038/s41467-023-37290-6.
Nat Commun. 2023.
PMID: 36964125
Free PMC article.
In female Balb/c mice intranasal administration of just 5 or 50 micrograms of TriSb92 as early as 8 h before but also 4 h after SARS-CoV-2 challenge can protect from infection. ...
In female Balb/c mice intranasal administration of just 5 or 50 micrograms of TriSb92 as early as 8 h before but also 4 h afte …